

Serveur Académique Lausannois SERVAL serval.unil.ch

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Malaria vaccine candidate: design of a multivalent subunit α -helical coiled coil poly-epitope.

Authors: Olugbile S, Villard V, Bertholet S, Jafarshad A, Kulangara C, Roussilhon C, Frank G, Agak GW, Felger I, Nebie I, Konate K, Kajava AV, Schuck P, Druilhe P, Spertini F, Corradin G

Journal: Vaccine

Year: 2011 Sep 16

Volume: 29

Issue: 40

Pages: 7090-9

DOI: 10.1016/j.vaccine.2011.06.122

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.



Published in final edited form as:

Vaccine. 2011 September 16; 29(40): 7090–7099. doi:10.1016/j.vaccine.2011.06.122.

Malaria vaccine candidate: design of a multivalent subunit α -helical coiled coil poly-epitope

Sope Olugbile^{1,*}, Viviane Villard², Sylvie Bertholet^{3,†}, Ali Jafarshad⁴, Caroline Kulangara⁵, Christian Roussilhon⁴, Geraldine Frank², George W Agak², Ingrid Felger⁵, Issa Nebie⁶, Karidia Konate⁷, Andrey V Kajava⁷, Peter Schuck⁸, Pierre Druilhe⁴, François Spertini¹, and Giampietro Corradin²

¹Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland ²Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland ³Infectious Disease Research Institute, Seattle, WA, 98104, U.S.A ⁴Malaria Vaccine Development Laboratory, Pasteur Institute, Paris, France ⁵Swiss Tropical Institute, Basel, Switzerland ⁶Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso ⁷CRBM, CNRS, University of Montpellier, Montpellier, France ⁸Laboratory of Cellular Imaging and Molecular Biophysics, NIBIB, NIH, Bethesda, MD, U.S.A

Abstract

A new strategy for the rapid identification of new malaria antigens based on protein structural motifs was previously described. We identified and evaluated the malaria vaccine potential of fragments of several malaria antigens containing α -helical coiled coil protein motifs. By taking advantage of the relatively short size of these structural fragments, we constructed different poly-epitopes in which 3 or 4 of these segments were joined together via a non-immunogenic linker. Only peptides that are targets of human antibodies with anti-parasite *in vitro* biological activities were incorporated. One of the constructs, **P181**, was well recognized by sera and peripheral blood mononuclear cells (PBMC) of adults living in malaria-endemic areas. Affinity purified antigen-specific human antibodies and sera from P181-immunized mice recognised native proteins on malaria-infected erythrocytes in both immunofluorescence and western blot assays. In addition, specific antibodies inhibited parasite development in an antibody dependent cellular inhibition (ADCI) assay. Naturally induced antigen-specific human antibodies were at high titers and associated with clinical protection from malaria in longitudinal follow-up studies in Senegal.

Introduction

It is estimated that there are up to 500 million cases of malaria every year and that about one million children living in sub-Saharan Africa die within the same period.¹ Over the past few years, appreciable progress has been made in the control of malaria infection in some parts of sub-Saharan Africa.² Further reduction in morbidity and mortality as well as possible

Corresponding author: Tel: +41 21 692 57 31, Fax: +41 21 692 57 05, Giampietro.Corradin@unil.ch.

*Biological Science Division, University of Chicago, Chicago, IL 60637, U.S.A.

†Current address: Novartis Vaccines & Diagnostics, 53100 Siena, Italy.

eradication of the disease will depend to a large extent on safe and effective vaccines. However there is currently no vaccine against malaria and only handful vaccine candidates are currently being evaluated.

The publication of the full genome of *Plasmodium falciparum*³ opened new opportunities for the development of novel drugs and vaccines against malaria. The aim of our group is to explore these vastly untapped data and discover new malaria antigens by combining bioinformatics and chemical peptide synthesis by using *in vivo/in vitro* parameters that are associated with protection against malaria. In our previous work⁴ we described the identification and production of 95 segments derived from 70 *P. falciparum*-3D7 erythrocytic stage proteins predicted to have α -helical coiled coil protein motifs. These α -helical coiled coil protein motifs consist of heptad repeats (abcdefg)_n with hydrophobic residues at **a** and **d** positions while the other residues are generally hydrophilic. The synthesized fragments readily assume their native oligomeric structure.⁵

Out of the 95 segments synthesized, 12 polypeptides were found to be targets of *in vivo* parasite growth inhibition in an ADCI assay. In order to maximize the proportion of the general host population that will respond to such a candidate vaccine while conserving the individual functional capacities of the constituent polypeptides (with additional likelihood of synergism), we then synthesized constructs consisting of 2-4 polypeptides joined together by the non-immunogenic a modified diethylene glycol linker (DEG). Selection of the constituent polypeptides was based on the length of each fragment, sequence conservation, antigenic recognition by semi-immune adult sera, immunogenicity in mice and biological activities of affinity purified specific human antibodies in ADCI assays.

Of the different poly-epitopes we constructed, we report here the results for **P181**, which is composed of the 3 fragments, **P90**, **P77** and **P27** that are derived from the proteins PFD0520c (25 kD), PF08_0048 (247 kD), PFF0165c (160 kD), respectively [Plasmodb.org; manuscript submitted]. These peptides had been identified as the most promising candidates in our previous analysis.⁴

Materials and Methods

Peptide synthesis and antigen characterization

The polypeptides were synthesized using solid-phase Fmoc chemistry⁶ with Applied Biosystem synthesizer 431A and 433A (Foster City, 179 CA). Derivatized diethylene glycol (DEG, Merck Chemicals Ltd, Nottingham, UK) was inserted in between the synthesis of the three fragments **P90**, **P77** and **P27** (TKKLNKELSEGKLEKLEKLEKLEKLEETNNTLENDIKV-DEG-EKLLKYNNEISSLKKELDILNEKMGKCT-DEG-KKRNVEEELHSLRKNYNIINEEIEEIT). The resulting construct was HPLC purified and the purity (>90%) was confirmed by analytic C18 HPLC and mass spectrometry (MALDI-TOF; Applied Biosystem) All reagents used were purchased from Fluka (Buchs, Switzerland) and Novabiochem (Laufelfingen, Switzerland). A custom-made synthesis was performed by Almac Sciences, Craigavon, Northern Ireland. Purity was >95% as judged by

analytical HPLC and mass spectrometry analysis shows material with the predicted MW of 11945.9 (data not shown).

The circular dichroism spectrum of the constructs was assessed with a JASCO J-810 spectrometer (JASCO Corporation, Japan). The measurements were with 0.2 mg/ml of the construct dissolved in water at 22°C and at pH 7.3.

Analytical ultracentrifugation was carried out in ProteomeLab XL-I analytical ultracentrifuges (Beckman Coulter, Palo Alto, CA). Sedimentation velocity experiments followed the standard protocol.⁷⁻⁹ In brief, peptide P181 samples at final concentrations of 0.1, 0.2, 0.4, and 0.8 mg/ml were dialyzed into a buffer composed of 14 mM NaCl, 0.3 mM KCl, 0.4 mM sodium phosphate, 0.2 mM potassium phosphate, pH 7.4 and sedimented at 59,000 rpm at 10°C. Interference optical fringe shift profiles were fitted with the $c(s)$ model.¹⁰ For the partial-specific volume, a value of 0.739 ml/g was predicted for the temperature-corrected partial specific volume from the amino acid composition and the tabulated data from Cohn & Edsall¹¹ and the density of PEG.¹² The density and viscosity of the buffer were measured using a DMA5000 densimeter and an AMVn automated micro viscometer (both from Anton Paar, Graz, Austria), respectively. The prediction of hydrodynamic parameters from model structures was based on the program BEST [please insert new reference to the following paper <http://www.ncbi.nlm.nih.gov/pubmed/15116362>].

Sedimentation equilibrium experiments were conducted following the standard protocol.⁷ In brief, 180 microliter samples at concentrations of 0.1, 0.3, and 1.0 mg/ml were sedimented to attain equilibrium at 25,000 rpm and 34,000 rpm at 10°C. Absorbance optical scans were acquired at 280 nm. The global analysis of all data sets was performed with the software SEDPHAT^{10,13} using the principle of soft mass conservation,¹⁴ and a model for monomer-dimer self-association in chemical and sedimentation equilibrium following mass action law, accounting for a non-participating species. Error estimates were obtained from Monte-Carlo analysis using 1000 iterations and a confidence level of one standard deviation.

Human sera

Anonymized archived human serum samples from malaria endemic areas and from Switzerland were used. The sera samples were collected from malaria-endemic regions of Burkina Faso, Tanzania, Papua New Guinea and Senegal and were the same samples used in our previous study.^{4,15} Briefly, the samples from Burkina Faso were collected from donors living in the village of Goundry in the province of Oubritenga. Ethical approval was obtained from the Ministry of Health, Burkina Faso. The Tanzanian samples were obtained from donors in Kikawila village in Morogoro region. Ethical approval was obtained from the Tanzanian Commission for Science and Technology. Additional sera samples obtained from Papua New Guinea were collected in the Maprik District of the East Sepik Province, during a cross sectional survey in July 1992 within the framework of the Malaria Vaccine Epidemiology and Evaluation Project (MVEEP) supported by the United States Agency for International Development. The area is highly endemic for malaria. Ethical clearance for MVEEP was obtained from the Papua New Guinea Medical Research Advisory Committee. Blood samples were obtained by venipuncture into tubes containing EDTA. The study

design in Senegal received clearance from the national Senegalese ethical committee. Negative control samples were Swiss adult donors with no history of malaria and no previous travel to malaria-endemic areas.

Human PBMCs

PBMC were obtained from adult donors living in Lagos, South-West Nigeria where malaria transmission is high all year round with seasonal peaks during the rainy season. Ethical approval was obtained from Lagos State University Teaching Hospital (LASUTH) ethical review committee.

Antigen recognition by human sera

The recognition of **P181** and each of its constituent polypeptide was assessed by ELISA with sera of adults living in malaria endemic regions of Burkina Faso, Tanzania, Papua New Guinea and Senegal. Each well in a 96-well microtiter plate (Maxisorb F96, Nunc, Roskilde, Denmark) was coated with 50 µl of each antigen (concentration 1 or 5 µg/ml for P181 and single fragments, respectively) and incubated overnight in humid chamber at 4°C. Wells were washed 4 times with PBS-0.05% Tween-20 and blocked for 1 h with 200 µl per well of 5% milk PBS-0.05% Tween-20. Sera of adults living in Burkina Faso (n=37) and Tanzania (n=42) were added at 1:200 diluted in 2.5% milk PBS-0.05% Tween-20. This was incubated for 1 h at room temperature. The plates were then washed and 50 µl/well of alkaline phosphatase-conjugated goat anti-human polyvalent immunoglobulin (Sigma, MO, USA) was added at 1:1000 dilutions. Wells were washed before 50 µl of nitrophenylphosphate solution (Sigma, MO, USA) was added. OD was measured at 405 nm. The negative controls (n=8) were sera of adult Europeans with no previous history of malaria or travel to malaria-endemic region. Test samples were considered positive when the measured OD was higher than that of the sum of average OD and 3SD of the negative controls.

T-cell proliferation

Frozen PBMCs collected from adult donors living in Nigeria were thawed and counted. Five replicates containing 2×10^5 cells/well were cultured with 10 µM of each of the constituent polypeptide and 5 µM of **P181**, respectively. The complete culture medium used consisted of RPMI (Sigma) supplemented with glutamine, 100 IU/ml Penicillin-Streptomycin, 100 µM non-essential amino acids, Kanamycin (Invitrogen, Paisley, UK), 2 mM sodium pyruvate (Invitrogen) and 8% human AB serum (Blutspendendienst SRK, Bern, Switzerland). The positive control was a mixture of tetanus toxoid (Pasteur Merieux, Lyon, France), *Mycobacterium tuberculosis* purified protein derivatives (PPD) (SSI, Copenhagen, Denmark) and *Candida* (NIBSC, London, UK).

On day 5, 1 µCi of thymidine diluted in the culture medium was added. The cultures were harvested 24 hours later, and radioactivity was measured as count/min. The stimulation index (SI) was calculated as (average count/min)/(count/min in culture without antigens). SI >2 was considered significant.

Immunogenicity in mice

Two syngeneic and one outbred strains of mice, C3H, CBF1 and ICR respectively (mice, 4 mice/group) were injected with 20 µg of the poly-epitope **P181** or with each of the constituent polypeptides (**P90**, **P77** and **P27**) formulated in Montanide ISA 720 (35 µg/mouse). Immunogenicity of **P181** formulated with Alhydrogel (1 mg/mouse) and GLA-SE (20 µg/mouse), an oil-in water stable emulsion containing a lipid A-like synthetic compound¹⁶⁻¹⁷ was also assessed in C3H, CBF1 and ICR mice. Each mouse was injected either subcutaneously at the base of the tail (Montanide and GLA-SE, 50 µl/mouse) or intraperitoneally (Alum, 500 µl/mouse) at 0, 3 and 8 weeks. The induced antibody responses were assessed by ELISA 10 days following second and third immunizations. Antibody titers were assessed by 1:3 serial dilutions of the sera starting from 1:100. The ELISA protocol used was same as that described above for human antibodies with the exception for mouse polyvalent immunoglobulin (Sigma, MO, USA) as second antibody. The end point is taken as the last dilution with OD value greater than average OD of control sera + 3SD.

Affinity purified human antibodies

Human antibodies specific for the poly-epitope **P181** and the constituent polypeptides were purified from pooled sera (50 ml) of adults living in Papua New Guinea. The pooled serum was centrifuged at 3,000 rpm for 5 min and the supernatant was filtered and further diluted at 1:5 in PBS/0.5 M NaCl. Two to five mg of each polypeptide was coupled with CNBr-activated Sepharose 4B (Amersham Biosciences, Bülendorf, Switzerland). The serum solution was then mixed with the antigen-coupled beads and stirred on wheel overnight at 4°C. The solution was then centrifuged at 3,000 rpm for 20 min and the beads were washed twice first with 5 ml of 20 mM Tris/0.5 M NaCl and then with 20 mM Tris. The specific antibodies were eluted with 0.1M glycine pH 2.5 at room temperature. Three fractions were collected in 100 µl of neutralization solution (10 PBS, pH 7.4). Antibodies were filtered through a 0.22 µm syringe filter, aliquoted and stored at -80°C. The antibody concentration was determined by the absorbance of each fraction at 280 nm.

Immunofluorescence assay (IFA)

For indirect immunofluorescence microscopy, infected RBCs were smeared onto glass slides and fixed in ice-cold acetone:methanol (1:1, vol/vol) for 10 min. Slides were blocked for 1h in 3%BSA/PBS and probed with one of the following primary and secondary antibodies: mouse anti-**P27** (1:200), mouse anti-P90 (1:200) mouse anti-P77 (1:200), human affinity purified sera specific to **P27** (1:2000) P90 (1:1000) and P77 (1:500), Cy3-labelled anti-mouse IgG (1:500), Cy3-labelled anti-human IgG (1:500; Jackson ImmunoResearch, Suffolk, UK) and Alexa 488-conjugated anti-rabbit IgG (1:200; Invitrogen). The slides were mounted in vectashield (Vector Laboratories, Burlingame, CA, USA) supplemented with DAPI for nucleus staining. Fluorescence microscopy was performed on a Leica fluorescence microscope DM-5000B using the × 60 oil immersion lens and documented with Leica DC200 digital camera system.

Western Blot analysis

Protein extracts were separated on a 10% SDS-polyacrylamide gel and transferred to nitrocellulose (0.2 mm, Whatman Schleicher + Schuell, Florham Park, NJ) under cooling conditions for 1 h at 80V and an additional hour at 100V. The membrane was blocked for 1 h in PBS/3% milk powder at room temperature and the primary antibody was diluted 1:500 in PBS and 1.5% milk powder. The membrane was incubated in the primary antibody solution overnight at 4°C, washed 8× in PBS, 0.05% Tween 20 and incubated with a peroxidase-conjugated goat anti-mouse IgG antibody (1:3000, Sigma). Bound secondary antibodies were visualized using Western Lightning® (PerkinElmer Life Sciences, Schwerzenbach, Switzerland).

Antibody dependent cellular inhibition (ADCI) assay

The inhibition of *P. falciparum* (3D7 strain) growth *in vitro* in the presence of human monocytes (MN) and antigen-specific antibodies was carried out by methods described elsewhere.¹⁸⁻¹⁹ Mature schizonts from a synchronized parasite culture were diluted at starting parasitemia of 0.5 % in normal human AB⁺ type RBCs and the hematocrit was adjusted to 2.5% with RPMI 1640 culture medium. Duplicate assays were set up in preheated 96-wells flat bottom sterile plastic plates (TPP, Trasadingen, Switzerland) containing 2×10^3 MN/well and by addition of 50 µl of parasite culture mixed with 50 µl of RPMI and various dilutions of each pool of sera at final concentration of 0.5%-10%. Control wells with parasite culture and RPMI were done in parallel. The plates were incubated in a candle jar at 37°C, in a 5% CO₂ incubator for 96 h. Thin blood smears for each well were fixed in methanol and stained in eosin and methylene blue. The parasitemia was determined by microscopic examination and counting of at least 5,000 RBCs in duplicate. The Specific Growth Inhibitory index (SGI) which estimates the parasite growth inhibition due to the effect of test Abs cooperating with MN was calculated as follows: $SGI = 100 \times (1 - (\% \text{ parasitemia with MN and test Abs} / \% \text{ parasitemia with MN and N-IgG} / \% \text{ parasitemia N-IgG}))$.

For each Ab tested, duplicate wells included the following controls: 1) non-specific monocytic inhibition, both MN + parasite, and MN + normal (N)-IgG + parasites and 2) direct inhibition by control or test IgG, both N-IgG + parasites, and test Abs + parasites. Pooled immunoglobulins of Africans (PIAG) and N-IgG were used at a final concentration of 1 mg/ml and as positive and negative controls, respectively. Immunopurified test human Abs were used at 15µg/ml while mouse sera were used at different dilutions.

Human antibody response and association with protection

The inhabitants of Ndiop village, in Senegal (with 300-350 villagers), where malaria transmission is seasonal, were involved in a prospective study using a stringent protocol of clinical follow-up including the daily active surveillance of each villager by a medical staff present seven days a week and 24 hours a day. The presence of each individual was checked on a daily basis and each febrile episode was recorded. A malaria attack was defined as an episode of fever with temperature $\geq 38.5^\circ\text{C}$ associated with a parasite density exceeding a parasite threshold of 3000 parasites/µl. Therefore both the occurrence of clinically defined malaria attacks and the actual time spent in Ndiop by each villager were available and

included in statistical analyses. The informed consent of each villager enlisted in this protocol (or that of the parents in the case of children) was obtained at the beginning of the study and was renewed at the beginning of each year of the survey. The study design received clearance from the national Senegalese ethical committee.²⁰

Antibody responses determined in Ndiop village were tested by multivariate analysis using stepwise regression process available in the JMP® (SAS) software. The number of malaria attacks identified during the 3 years of active follow-up following the plasma sampling was used as a Log10+1-transformed continuous variable. Both age and Log10-transformed antibody responses were simultaneously tested as explanatory variables and controlled for to explain the number of malaria attacks identified for each individual. The F ratios, (i.e., the ratio of the mean square for the effect divided by the mean square of the error) were calculated as well as probabilities associated with F ratio values (i.e., the probability was tested that, given that the null hypothesis was true, an even larger F statistic would occur due to random error).²¹

Results

Synthetic polypeptides consisting of 2-4 fragments with α -helical coiled coil protein motif described in our previous publication⁴ were co-linearly synthesized by using a non-immunogenic linker, di-ethylene glycol (DEG). The **P181** construct is composed of **P90** (38 amino acids), **P77** (28 amino acids) and **P27** (27 amino acids) fragments with a modified diethylene glycol inserted between the fragments (see Materials and Methods). The selection of these 3 among 12 candidates that were previously identified,⁴ was guided by the frequency of recognition by human antibodies, their *in vitro* biological activities, immunogenicity in mice and fragment length to obtain a poly-epitope amenable to peptide synthesis.²² The linking of the 3 epitopes stabilizes the α -helical conformation of the single epitopes as seen in Fig. 1. In fact, the CD profile of **P181** with minima at 207 and 222 nm and a high intensity band at 207 nm indicates a high content of α -helical structures in contrast to those of the single epitopes.

The sedimentation coefficient distribution $c(s)$ exhibited distinct peaks of approximately equal areas at $s_{20,w}$ values of ~ 1.2 S and ~ 1.8 S, with a best-fit average frictional ratio of ~ 1.41 corresponding to species of ~ 10 kDa and 18 kDa. Within the typical error of this analysis, this strongly suggests the presence of monomers and dimers. The measured frictional ratio is best consistent with hydrodynamic properties of the moderately compact structures in Figure 2, 1 and 2, rather than the most extended form 3.

In order to examine the association state in more detail, we next performed sedimentation equilibrium experiments with samples at several loading concentrations. Cell-average molecular weights were in between that of the monomer and dimer. The global analysis with a monomer-dimer self-association model resulted in an estimated equilibrium constant of $K_D = 115 (\pm 15) \mu\text{M}$.

Antigenic recognition

Sera—The majority of the adult donor population living in Burkina Faso, Tanzania and PNG recognized the constituent fragments (range 52-83%, Table 1). The prevalence of recognition of the poly-epitope was similar or higher than the individual components (73%, 79% and 90% respectively for BF, TZ and PNG samples). As expected, average ELISA OD values for P181 were higher than those observed for the individual epitopes.

T-cell proliferation—Peripheral blood mononuclear cells of adults living in malaria-endemic region of South-West Nigeria (12 out of 13) proliferated when incubated with **P181** solution. This proportion was relatively higher than that of the single constituents (range 23-54%). In addition, the average SI obtained with **P181** (9.8) was also higher as compared to that obtained with each peptide (2.2-3.2; Table 2).

Human antibodies specific for P181

Human antibodies specific for **P181** and each of its constituents were obtained from pools of sera obtained from adults living in Papua New Guinea. The reactivity and specificity of purified antibodies were confirmed by ELISA (Table 3). Antibodies specific for each of the components recognized the **P181**. Likewise, anti-**P181** antibodies recognized each of the individual fragments.

The **P181**-specific mouse or human antibodies recognized parasite structures on *P. falciparum*-infected erythrocytes in IFA (Fig. 3a). They also produced distinct bands by western blotting of infected erythrocyte lysates (Fig. 4a).

Immunogenicity in mice

High antibody titers were induced in inbred and outbred mice immunized with **P181** formulated with Alhydrogel, GLA-SE and Montanide AS 720 in several strains of mice. The induced antibodies also recognized all or part of the individual constituents depending on the adjuvant or mouse strain used (Table 4a and b). Similarly, anti-sera specific for **P27**, **P77** and **P90** recognize the poly-epitope.

All mouse sera recognized parasite structures in malaria-infected erythrocytes by IFA (Fig. 3b) and in lysates in Western blots (Fig. 4b). PF08_0048 has a predicted size of 247 KDa, thus the full length protein was not detected on Western Blots.

ADCI and association with protection

For ADCI experiments, only those experiments in which an optimal growth rate of the parasite was obtained (e.g. >6-fold increase per 48 h), were kept for analysis. Table 5 shows the SGI values obtained as compared to the positive control, the pool of Ivory Coast adult immunoglobulins previously employed in passive transfer experiments in humans. As the ADCI assay is not a quantitative assay and because there is a dose dependent increase in ADCI activity only at very low antibody concentrations [19], whereas, at higher concentration, there is a plateau of activity, all tested antibodies were assessed at a single antibody concentration of 15 µg/ml.

To assess the association with protection longitudinal follow-up studies were performed among inhabitants of Dielmo, Senegal. The first study involved 45 individuals among whom 22 had no malaria attack during a 3-year follow-up period and 23 had one or more malaria attacks during the same period. Both have the same age-distribution. These results were also confirmed among 102 Ndiop inhabitants while also adjusting for age and occurrence of malaria attacks.

In multivariate analysis, when both age and the time spent in the village were systematically controlled in each statistical test, antibodies to **P27** were high when the number of malaria attacks was low after 1 and 3 years of active and daily clinical follow-up of the villagers (after 1-year F ratio = 8.92 and p = 0.0047, after 3 years F ratio = 11.74; p = 0.0012; Table 6). For **P181**, after 1 year of follow-up, the F ratio was 11.43; p = 0.0016 whereas after 3 years of study, the F ratio was 15.48; p = 0.0003). For a given age and a determined period of presence in the village, a two-fold increase in anti-**P27** antibody response was potentially associated with a 1.5-fold decrease in the number of malaria attacks expected to occur after 3 years of follow-up. The mean age of the cohort studied was 16.1 ± 11.1 years. The mean period of time spent in the village was 319 ± 85 days during the first year of follow-up (i.e. people remained continuously in the village during 87.4% of the year) and 862 ± 282 days during the 3 years of follow-up (people remained permanently in the village during 78.6% of the 3 year period). A two-fold increase in anti-**P181** antibody responses was potentially linked with a 1.6 fold reduction in the number of malaria attacks expected during the same period of study. The marked association between protection and anti-**P181** responses reflects the contribution of the results obtained when testing anti-**P27** antibody responses; the representation of **P27** epitopes within the multi-epitope construct also suggests that anti-**P27** constitute a substantial part of Abs to **P181**.

Discussion

As a follow-up to our previous studies^{4,23} in which several novel B cell epitopes were identified as possible targets of a protective immune response against *P. falciparum*, we describe here the evaluation of a poly-epitope constructed by selecting 3 promising fragments, **P90**, **P77** and **P27** derived from 3 novel proteins PFD0520c, PF08_0048, PFF0165c. By combining fragments with specific immunological properties (e.g high antigenicity, high immunogenicity, association with protection in humans, high activity of specific antibodies in ADCI assay), we attempted to integrate these features in a single construct and, thus, increase the capacity of the poly-subunit antigen to induce effective immune responses in a genetically heterogeneous human populations since each fragment can act as a helper T-cell epitope. Use of hybrid recombinant constructs as vaccine candidates has already been applied for malaria, influenza, HIV, tuberculosis and allergy.²⁴⁻²⁸

With regard to the structural characteristics of **P181**, the data obtained by CD and analytical ultracentrifugation measurements indicate that the poly-epitope has a high content of α -helical structure, and is a dimer in equilibrium with its monomer, thus, suggesting a two-strand α -helical coiled coil conformation (Fig. 2). Indeed, recombinant protein PFD0520c, from which **P90** is derived, has also been determined to be a dimer with high α -helical

structure content (manuscript in preparation), and **P27** is predicted to fold as a dimer. The linking together of several epitopes stabilises the α -helical structure of individual components as indicated by the CD data. Changing the order of peptides in the poly-epitope does not seem to substantially change the physico-chemical and immunological properties of the new construct (data not shown).

The resemblance of the poly-epitope structure to that assumed by the individual fragments within the corresponding proteins has been the basis of our initial epitope selection, and is of paramount importance to the identification and development of an erythrocytic malaria vaccine where protection is mediated by antibodies.

With regards to the antigenic properties of **P181**, the poly-peptide was better recognized by antibodies (similar or higher prevalence and higher average OD) and by PBMC from Nigerian donors in terms of prevalence and SI. Similarly, when considering immunogenicity in mice, the poly-epitope was generally more immunogenic in terms of antibody titers than the individual fragments. In addition, it provided T-cell help to those individual antigens, which were not immunogenic by themselves in certain strains (see **P90**, for example; table 4a). This concept is important when considering the use of **P181** as vaccine candidate in humans with respect to a mixture of single components.

Affinity-purified human antibodies and mouse sera specific for **P181** and its components recognized parasitic structures in IFA and highlighted a limited number of proteins at MW consistent with the size of the corresponding parasitic proteins (24, 240 and 160 kD) or their fragments, except for anti-P90 antibodies which consistently failed to bind proteins of the 25 kD range (manuscript in preparation). Human specific antibodies to the 4 constructs are all active in ADCI, consistent with our previous observation for the constituent polypeptides.⁴ Of note however is the fact that the observed ADCI activity of **P181** is lower than that observed for **P27**, but higher than that seen for **P77** and **P90**. Thus, it reflects the mean ADCI activity of the individual components. Alternatively, this might reflect experimental variation in the ADCI assay, which is only a semi-quantitative assay, or a competition of different antibodies with Fc γ RII and Fc γ RIII receptors present on human monocytes.¹⁷ More work is needed to clarify this point. Finally, the association of the antibody response to protection from malaria indicate a stronger relationship with **P181** than for its single components. We would like to think that this is due to the better structural similarity of the poly-epitope to the native structure of the individual components.

In summary, given the higher prevalence and recognition of **P181** by natural antibodies in ELISA, its higher stimulation index in the T-cell proliferation assay, its greater immunogenicity in mice, together with the inhibitory activity of antibodies specific to **P181** as assessed by ADCI and with the strong association with protection from clinical malaria as determined in a 3-year longitudinal study in adults, **P181** appears to be a stronger vaccine candidate than the individual peptides and warrants a further development as a malaria vaccine.

Finally, since chemical synthesis of larger fragments are now possible,²¹ it is conceivable to design constructs similar to **P181** but with a wider immunological spectrum by including *P. falciparum* and *P. vivax* fragments.

Acknowledgments

This work was supported by the Swiss National Science Foundation grant 310000-112244 and by the grants of the Swiss Secretary for Education and Research (No 0536) in the context of Commission of the European Communities, Sixth Framework Programme, contract LSHP-CT-2003-503240, "Mucosal Vaccines for Poverty-Related Diseases" (MUVAPRED) and the Intramural Research Program of the NIBIB, NIH. We would like to thank Drs S. Reed and T. Vedvick for providing advice and GLA-SE whose work was supported by a grant#42387 from the Bill & Melinda Gates Foundation.

References

1. Hay SI, Okiro EA, Gething PW, Patil AP, Tatem AJ, Guerra CA. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. *PLoS Med.* 2010; 7(6) p. 1000290.
2. O'Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. *Lancet Infect Dis.* 2010; 10(8):545–55. [PubMed: 20637696]
3. Gardner MJ, Hall N, Fung E, White O, Berriman M, et al. Genome sequence of the human malaria parasite *Plasmodium falciparum*. *Nature.* 2002; 419(6906):498–511. [PubMed: 12368864]
4. Villard V, Agak GW, Frank G, Jafarshad A, Servis K, Nebie I, et al. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. *PLoS One.* 2007; 2(7):645.
5. Harbury PB, Zhang T, Kim PS, Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. *Science.* 1993; 262(5138):1401–7. [PubMed: 8248779]
6. Atherton, E.; Sheppard, RC. Solid phase synthesis; a practical approach. IRL Press, Oxford University Press; Oxford: 1989.
7. Balbo A, Brown PH, Braswell EH, Schuck P. Measuring protein-protein interactions by equilibrium sedimentation. *Curr Protoc Immunol.* 2007; Chapter 18 Unit 18 8.
8. Balbo A, Zhao H, Brown PH, Schuck P. Assembly, loading, and alignment of an analytical ultracentrifuge sample cell. *J Vis Exp.* 2009; (33)
9. Brown PH, Balbo A, Schuck P. Characterizing protein-protein interactions by sedimentation velocity analytical ultracentrifugation. *Curr Protoc Immunol.* 2008; Chapter 18 Unit 18 15.
10. Schuck, P. 2010. p. <https://sedfitsedphat.nibib.nih.gov/software/default.aspx>
11. Cohn, EJ.; Edsall, JT. Density and apparent specific volume of proteins. In: Cohn, EJ.; Edsall, JT., editors. *Proteins, Amino Acids and Peptides*. Princeton, NJ: Van Nostrand-Reinhold; 1943. p. 370-381.
12. Lepori L, Mollica V. Volumetric properties of dilute aqueous-solutions of poly(ethylene glycols). *J Polym Sci B.* 1978; 16(6):1123–1134.
13. Schuck, P. 2010. <https://sedfitsedphat.nibib.nih.gov/software/default.aspx>
14. Vistica J, Dam J, Balbo A, Yikilmaz E, Mariuzza RA, Rouault TA, et al. Sedimentation equilibrium analysis of protein interactions with global implicit mass conservation constraints and systematic noise decomposition. *Anal Biochem.* 2004; 326(2):234–56. [PubMed: 15003564]
15. Olugbile S, Kulangara C, Bang G, Bertholet S, Suzarte E, Villard V, et al. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage associated *Plasmodium falciparum* protein PFF0165c. *Infect Immun.* 2009; 77:5701–9. [PubMed: 19786562]
16. Anderson RC, Fox CB, Dutil TS, Shaverdian N, Evers T, Poshusta GR, et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. *Colloids Surf B Biointerfaces.* 2010; 75(1):123–32. [PubMed: 19748238]
17. Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton G, Vedvick T, et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. *Vaccine.* 2009; 27(23):3063–71. [PubMed: 19428920]

18. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against *Plasmodium falciparum* blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. *J Exp Med.* 1990; 172(6):1633–41. [PubMed: 2258697]
19. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, Druilhe P. A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcγRII and FcγRIII. *J Immunol.* 2007; 178(5):3099–106. [PubMed: 17312157]
20. Rogier C, Trape JF. Study of premunition development in holo- and meso-endemic malaria areas in Dielmo and Ndiop (Senegal): preliminary results, 1990-1994. *Med Trop (Mars).* 1995; 55(4 Suppl):71–6. [PubMed: 8649271]
21. Roussilhon C, Oeuvray C, Müller-Graf C, Tall A, Rogier C, Trape JF. Long-term clinical protection from *falciparum* malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. *PLoS Med.* 2007; 4(11):320.
22. Olugbile S, Habel C, Servis C, Spertini F, Verdini A, Corradin G. Malaria vaccines-The long synthetic peptide approach: Technical and conceptual advancements. *Curr Opin Mol Ther.* 2010; 12(1):64–76. [PubMed: 20140818]
23. Agak GW, Bejon P, Fegan G, Gicheru N, Villard V, Kajava AV. Longitudinal analyses of immune responses to *Plasmodium falciparum* derived peptides corresponding to novel blood stage antigens in coastal Kenya. *Vaccine.* 2008; 26(16):1963–71. [PubMed: 18342997]
24. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. *Nat Med.* 2011; 17(2):189–94. [PubMed: 21258338]
25. Kallinteris NL, Lu X, Wu S, Hu H, Li Y, Gulfo JV, et al. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. *Vaccine.* 2003; 21(27-30):4128–32. [PubMed: 14505892]
26. Kocken CH, Hundt E, Knapp B, Brazel D, Enders B, Narum DL, et al. Immunization of Aotus monkeys with recombinant *Plasmodium falciparum* hybrid proteins does not reproducibly result in protection from malaria infection. *Infect Immun.* 1998; 66(1):373–5. [PubMed: 9423884]
27. Linhart B, Hartl A, Jahn-Schmid B, Verdino P, Keller W, Krauth MT, et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. *J Allergy Clin Immunol.* 2005; 115(5):1010–6. [PubMed: 15867859]
28. Naruse H, Ogasawara K, Takami K, Kajino K, Gotohda T, Itoh Y, et al. Analysis of epitopic residues introduced into the hybrid peptide vaccines prepared according to the cassette theory. *Vaccine.* 1994; 12(9):776–82. [PubMed: 7526571]




Fig. 1. CD profile of P181 and its constituents




Fig.2. Structural model of P181




Fig. 3. (a) Immunofluorescence staining of *P. falciparum* infected erythrocytes with affinity purified human antibodies (**P27**, **P77**, **P90** and **P181** in red). First row: **P27** specific human antibodies indicate localization of the corresponding protein PFF0165c to the periphery of the RBC (in red). Nucleus stained with Hoechst (in blue), transmission light microscopy of the infected red blood cell (differential interference contrast, DIC) and merged picture of the nucleus and P27 specific antibody signal (merge). Second and third rows: **P77** or **P90** specific human sera indicate the localization of the corresponding proteins PF08_0048 or PFD0520c respectively to the cytoplasm of the parasite. Nucleus stained with Hoechst (in blue), transmission light microscopy of the infected red blood cell (DIC) and merged picture of the nucleus and P77 or P90 signal (merge). Fourth row: **P181** specific human antibodies. Signal at the periphery of the RBC and the cytoplasm of the parasite indicates that sera raised against the poly-epitope recognizes the three corresponding proteins PFF0165c,

PF08_0048 and PFD0520c. Nucleus stained with DAPI (in blue), transmission light microscopy of the infected red blood cell (DIC) and merged picture of the nucleus and P181 (merge).

(b) Immunofluorescence staining of *P. falciparum* infected erythrocytes with murine antibodies against **P27**, **P77**, **P90** or **P181**, respectively. First row: **P27** specific human antibodies indicate localization of the corresponding protein PFF0165c to the periphery of the RBC (in **red**). Nucleus stained with Hoechst (in **blue**), transmission light microscopy of the infected red blood cell (DIC) and merged picture of the nucleus and P27 specific serum signal (merge). Second and third rows: Localization of PF08_0048 and PFD0520c using mouse sera raised against **P77** and **P90** respectively (in **red**). Staining indicates localization of both proteins to the parasite cytoplasm. Nucleus stained with DAPI (in **blue**), transmission light microscopy of the infected red blood cell (DIC) and merged picture of the nucleus and P77 or P90 respectively. Fourth row: Signal in the infected RBC using mouse sera raised against the poly-epitope P181 (in **red**). Signal at the periphery of the RBC and the cytoplasm of the parasite indicates that sera raised against the poly-epitope recognizes the three corresponding proteins PFF0165c, PF08_0048 and PFD0520c. Nucleus stained with DAPI (in **blue**), transmission light microscopy of the infected red blood cell (DIC) and merged picture of the nucleus and P181 (merge).




Fig 4.
 (a) Immunoblot from saponin-lysed 3D7 late stage parasite extracts electrophoresed under reducing conditions. Immunoblot was probed with affinity purified human α -P181, α -P27, α -P77, α -P90, normal human serum (NHS) and affinity purified human α -MSP-2-3D7 which was used as a positive control. Relative size standards are indicated on the left in kDa.
 (b) Immunoblot from saponin-lysed 3D7 late stage parasite extracts electrophoresed under reducing conditions. Immunoblot was probed with mouse α -P181, α -P27, α -P77, α -P90, normal mouse serum (NMS) and α -R634 which was used as a positive control. α -R634 was

a second bleed sera obtained from rabbits immunized with recombinant MSP-2. Relative size standards are indicated on the left in kDa.

Table 1

Prevalence of positive donors

	Burkina Faso (N=37)			Tanzania (N=42)			Papua New Guinea (N=37)		
	Mean OD + 3SD (%)	OD Ratio (%)	Mean OD	Mean OD + 3SD (%)	OD Ratio (%)	Mean OD	Mean OD + 3SD (%)	OD Ratio (%)	Mean OD
P181	73	65	0.549	79	74	0.493	90	83	0.871
P90	62	41	0.340	83	43	0.270	86	62	0.450
P77	73	51	0.295	71	55	0.371	71	55	0.403
P27	63	43	0.310	52	31	0.279	83	64	0.520

Prevalence: % of donors whose serum gave an OD value in ELISA higher than the mean OD + 3 standard deviations of negative controls (naïve European donors) or OD ratio > or = 2. Sera dilution = 1:200. Mean OD comprises the mean of all OD.

Table 2
Human PBMC proliferation in the presence of different antigens

	Prev - (%)	SI
P181	92	9.8
P90	23	3.2
P77	54	3.1
P27	38	2.2

PBMC proliferation of adult donors living in Nigeria (N=13). Each antigen was put in culture in 200 μ l at 10 μ M (5 μ M for **P181**) together with 2×10^5 PBMC at 37°C for 5 days. The cultures were then pulsed overnight with 3 H-thymidine, and stimulation index (SI) was regarded significant when the radioactivity of stimulated over unstimulated cultures was ≥ 2 .

Table 3
Cross reactivity of human antigen-specific antibodies

	IgG anti-			
	P181	P90	P77	P27
P181	++++	++	+	+++
P90	+	+++	-	-
P77	+	-	++	-
P27	++	-	-	+++

Affinity purified antibodies specific for **P181** and its constituents recognize **P181** and its constituents and vice-versa (+ to ++++ represent positive ELISA at dilutions 1:300 to 1:8100).

Table 4
a. Immunogenicity of P181 and its constituents in mice immunized with Montanide ISA 720 and cross-reactivity of specific sera

Immunogen	Mice	Antigen	GMT	SD	Responders
P181	CB6F1	P181	5.10	0.28	4/4
		P90	3.20	0.90	3/4
		P27	4.50	0.24	4/4
	C3H	P77	4.46	0.72	4/4
		P181	5.34	0.00	3/3
		P90	4.54	0.28	3/3
		P27	4.04	0.55	3/3
ICR	P77	4.70	0.28	3/3	
	P181	4.97	0.46	4/4	
	P90	2.79	1.17	2/4	
	P27	4.32	0.87	4/4	
P27	CB6F1	P77	3.77	0.46	4/4
		P27	4.08	0.43	5/5
		P181	4.68	0.55	5/5
	C3H	P27	5.10	0.34	4/4
		P181	5.34	0.00	4/4
	ICR	P27	3.90	0.39	4/4
		P181	4.73	0.46	4/4
P77	CB6F1	P77	4.70	0.72	4/4
		P181	nd		
	C3H	P77	5.00	0.55	3/3
		P181	4.22	0.28	3/3
	ICR	P77	4.98	0.24	4/4
		P181	4.70	0.72	4/4
		P90	2.00	0.00	0/4
P90	C3H	P181	nd		
		P90	5.00	0.60	4/4

Immunogen	Mice	Antigen	GMT	SD	Responders
		P181	4.86*		
	ICR	P90	2.98	0.81	2/4
		P181	2.33	0.46	0/4

GMT titers of immune sera determined as last dilution with OD higher than OD control serum + 3 SD. Responder animal is arbitrarily considered positive if GMT value is ≥ 3 .

* pool of 4 sera

Table 4b: Immunogenicity of P181 in mice immunized with different adjuvants and serum cross-reactivity.

Adjuvant	Mice	Antigen	GMT	SD	Responders
GLA-SE	C3H	P181	5.00	0.55	3/3
		P90	2.28	0.55	0/3
		P27	3.89	0.48	3/3
	CB6F1	P77	4.68	0.55	3/3
		P181	3.77	0.46	4/4
		P90	2.00	0.00	0/4
		P27	2.86	0.87	2/4
	ICR	P77	2.11	0.24	0/4
		P181	4.45	0.67	9/9
		P90	2.18	0.42	0/9
P27		4.00	0.84	8/9	
P77		3.38	0.62	5/8	
Alum	C3H	P181	5.34	0.00	4/4
		P90	5.10	0.28	4/4
		P27	4.97	0.46	4/4
	CB6F1	P77	5.34	0.00	4/4
		P181	4.15	0.72	5/5
		P90	2.09	0.21	0/5
		P27	3.14	0.26	2/5
	ICR	P77	3.50	1.37	3/5
		P181	4.21	1.14	6/7
		P90	2.43	0.55	1/7
	P27	3.57	1.03	5/7	

Table 4b: Immunogenicity of P181 in mice immunized with different adjuvants and serum cross-reactivity.

Adjuvant	Mice	Antigen	GMT	SD	Responders
		P77	3.96	1.06	6/7

GMT titers of immune sera determined as last dilution with OD higher than OD control serum + 3 SD. Responder animal is arbitrarily considered positive if GMT value is ≥ 3 .

Table 5
***In vitro* inhibition of *P. falciparum* 3D7 strain by human affinity purified antibodies specific for P181 and its constituent peptides**

	SGI*
P181	55%
P90	43%
P77	36%
P27	106%

* SGI- specific growth inhibition of human specific antibodies.

Table 6

The antibody responses found in Ndiop were tested in multivariate analysis by stepwise regression. The number of malaria attacks identified during the 3 years following the serum sampling was used as a continuous variable. Both age and Log10-transformed antibody responses were simultaneously tested as explanatory variables.

Anti-peptide IgGs:	F ratios:	<i>p</i> values:
IgG1-P27	11.74	0.001
IgG3-P77	3.31	0.076
IgG1-P90	0.88	0.354
IgG1-P181	15.48	0.0003

The F ratio, (i.e., the ratio of the mean square for the effect divided by the mean square of the error) was calculated, and F statistics were used in order to determine that the effect test was null. By testing the hypothesis that the lack of fit was zero, the F test indicated if all parameters of an individual effect were null. The probabilities indicated in the Table correspond to the significance levels determined for the F ratio values (i.e. the probability that given that the null hypothesis is true, an even larger F statistic would occur due to random error). Using Bonferroni correction (i.e. taking into account that 18 different statistical tests were carried out), individual *p* values < 0.0028 can still be considered as significant.